dpp-4 inhibitor and glp-1 receptor agonist combination versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Role of Dipeptidyl Peptidase 4

If your primary research goal is maximum weight reduction and you are willing to manage more side effects to get there, retatrutide is the strongest monotherapy option available

Because of these effects, patients taking GLP-1 agonist medications may need fewer sessions per week or longer ramp up periods with resistance training than never-obese counterparts

These metabolic differences are generally modest compared to the dramatic difference in total weight loss

10.7759/cureus.38630 49 KnezevichE.CrnicT.KershawS.DrincicA

The hypothesis was that tirzepatide would reduce LV mass and epicardial adipose tissue (EAT) in these patients